~~<i id='132F884D98'><strike id='132F884D98'><tt id='132F884D98'><pre id='132F884D98'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：fashion 2025-09-30 13:53:20 Page View：87228

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How the first Native Hawaiian psychiatrist helped diversify medicine
Next article： How one medical school became remarkably diverse

explore

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

How to make over

AdobeTheFoodandDrugAdministrationrecentlyapprovedOpill,thefirstover-the-counteraccessbirthcontrolpil

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Mysisterhasafantasyaboutouroldage:Sheimaginesthatthesevensiblingsinourfamilywillbelivingtogetheragai